Literature DB >> 20179191

Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.

Amit Maity1, Eric J Bernhard.   

Abstract

The tumor microenvironment is a key factor in cancer treatment response. Recent work has shown that changes in the tumor vasculature can be achieved by inhibiting tumor cell signaling, resulting in enhanced tumor oxygenation. These changes could promote responses to both chemo- and radiation therapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20179191      PMCID： PMC2840203          DOI： 10.1158/0008-5472.CAN-09-3615

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Tumour biology: herceptin acts as an anti-angiogenic cocktail.

Authors:  Yotaro Izumi; Lei Xu; Emmanuelle di Tomaso; Dai Fukumura; Rakesh K Jain
Journal:  Nature       Date:  2002-03-21       Impact factor: 49.962

3.  Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.

Authors:  A Maity; N Pore; J Lee; D Solomon; D M O'Rourke
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

4.  Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.

Authors:  J Rak; Y Mitsuhashi; C Sheehan; A Tamir; A Viloria-Petit; J Filmus; S J Mansour; N G Ahn; R S Kerbel
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

5.  Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.

Authors:  D Fukumura; L Xu; Y Chen; T Gohongi; B Seed; R K Jain
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

6.  The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.

Authors:  E Cohen-Jonathan; S M Evans; C J Koch; R J Muschel; W G McKenna; J Wu; E J Bernhard
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

7.  Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules.

Authors:  Benjamin J Moeller; Yiting Cao; Chuan Y Li; Mark W Dewhirst
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

8.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.

Authors:  T G Graeber; C Osmanian; T Jacks; D E Housman; C J Koch; S W Lowe; A J Giaccia
Journal:  Nature       Date:  1996-01-04       Impact factor: 49.962

9.  Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.

Authors:  C Hess; V Vuong; I Hegyi; O Riesterer; J Wood; D Fabbro; C Glanzmann; S Bodis; M Pruschy
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

10.  Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors.

Authors:  Ricky T Tong; Yves Boucher; Sergey V Kozin; Frank Winkler; Daniel J Hicklin; Rakesh K Jain
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701
View more
  16 in total

1.  Tumor vascular microenvironment determines responsiveness to photodynamic therapy.

Authors:  Amanda L Maas; Shirron L Carter; E Paul Wileyto; Joann Miller; Min Yuan; Guoqiang Yu; Amy C Durham; Theresa M Busch
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

2.  A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.

Authors:  S Leong; S G Eckhardt; E Chan; W A Messersmith; J Spratlin; D R Camidge; S Diab; R Khosravan; X Lin; E Chow Maneval; A C Lockhart
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

Review 3.  Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.

Authors:  Amanda J Walker; Sara R Alcorn; Amol K Narang; Katriana M Nugent; Aaron T Wild; Joseph M Herman; Phuoc T Tran
Journal:  Curr Probl Cancer       Date:  2013-10-05       Impact factor: 3.187

4.  NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Authors:  Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker
Journal:  J Natl Cancer Inst       Date:  2012-12-10       Impact factor: 13.506

5.  DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines.

Authors:  Mitsutoshi Kadowaki; Hiroki Yoshioka; Hideki Kamitani; Takashi Watanabe; Paul A Wade; Thomas E Eling
Journal:  Int J Cancer       Date:  2011-05-25       Impact factor: 7.396

6.  Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

Authors:  Nagaraj S Nagathihalli; Jason A Castellanos; Chanjuan Shi; Yugandhar Beesetty; Michelle L Reyzer; Richard Caprioli; Xi Chen; Alex J Walsh; Melissa C Skala; Harold L Moses; Nipun B Merchant
Journal:  Gastroenterology       Date:  2015-08-07       Impact factor: 22.682

7.  PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Authors:  Girija Dasmahapatra; Hiral Patel; Tri Nguyen; Elisa Attkisson; Steven Grant
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

Review 8.  Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.

Authors:  Salma K Jabbour; Terence M Williams; Mutlay Sayan; Eric D Miller; Jaffer A Ajani; Andrew C Chang; Norman Coleman; Wael El-Rifai; Michael Haddock; David Ilson; Daniel Jamorabo; Charles Kunos; Steven Lin; Geoffrey Liu; Pataje G Prasanna; Anil K Rustgi; Rosemary Wong; Bhadrasain Vikram; Mansoor M Ahmed
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

9.  NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.

Authors:  Emmanouil Fokas; Michio Yoshimura; Remko Prevo; Geoff Higgins; Wolfgang Hackl; Sauveur-Michel Maira; Eric J Bernhard; W Gillies McKenna; Ruth J Muschel
Journal:  Radiat Oncol       Date:  2012-03-27       Impact factor: 3.481

10.  Silencing UHRF1 Enhances Radiosensitivity of Esophageal Squamous Cell Carcinoma by Inhibiting the PI3K/Akt/mTOR Signaling Pathway.

Authors:  Beina Hui; Shupei Pan; Shaomin Che; Yuchen Sun; Yanli Yan; Jia Guo; Tuotuo Gong; Juan Ren; Xiaozhi Zhang
Journal:  Cancer Manag Res       Date:  2021-06-21       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.